According to a recent overview by HCM specialists at the Lahey Clinic, the prognosis for patients with hypertrophic cardiomyopathy and atrial fibrillation has substantially improved in recent years.
The use of direct anti-coagulant drugs like Pradexa, Xarelto and Eliquis, which began in 2010, has had a major impact in reducing stroke risk in HCM patients who suffer from Afib. And, there is a low threshold for the initiation of these drugs for HCM patients who experience episodes of atrial fibrillation, even if such episodes are sporadic or infrequent. Also, anti-arrhythmic drugs as well as catheter and surgical ablation procedures can be helpful treatment options which are available to these patients.
There are also behavior modifications which can have a positive impact on Afib since patients who are overweight or who suffer from obstructive sleep apnea have a higher risk for atrial fibrillation.
Featured below are some past articles on HCMBeat about atrial fibrillation:
Atrial Fibrillation May Cause Negative Outcomes in HCM
Atrial Fibrillation? Try Giving Up Alcohol
Atrial Fibrillation: Treatable HCM Complication
Better Screening and Treatment Necessary for Atrial Fibrillation
HCM Beat 